nodes	percent_of_prediction	percent_of_DWPC	metapath
Atazanavir—ABCC1—Epirubicin—urinary bladder cancer	0.114	0.156	CbGbCtD
Atazanavir—ABCB1—Mitomycin—urinary bladder cancer	0.104	0.143	CbGbCtD
Atazanavir—ABCC1—Etoposide—urinary bladder cancer	0.0887	0.121	CbGbCtD
Atazanavir—SLCO1B3—Methotrexate—urinary bladder cancer	0.0848	0.116	CbGbCtD
Atazanavir—ABCC1—Doxorubicin—urinary bladder cancer	0.0605	0.0828	CbGbCtD
Atazanavir—ABCC1—Methotrexate—urinary bladder cancer	0.0586	0.0803	CbGbCtD
Atazanavir—CYP3A4—Thiotepa—urinary bladder cancer	0.0473	0.0648	CbGbCtD
Atazanavir—ABCB1—Gemcitabine—urinary bladder cancer	0.03	0.0411	CbGbCtD
Atazanavir—CYP2C9—Fluorouracil—urinary bladder cancer	0.0264	0.0362	CbGbCtD
Atazanavir—CYP2C9—Cisplatin—urinary bladder cancer	0.0224	0.0307	CbGbCtD
Atazanavir—ABCB1—Cisplatin—urinary bladder cancer	0.0218	0.0298	CbGbCtD
Atazanavir—ABCB1—Etoposide—urinary bladder cancer	0.0214	0.0293	CbGbCtD
Atazanavir—ABCB1—Doxorubicin—urinary bladder cancer	0.0146	0.02	CbGbCtD
Atazanavir—ABCB1—Methotrexate—urinary bladder cancer	0.0141	0.0194	CbGbCtD
Atazanavir—CYP3A4—Etoposide—urinary bladder cancer	0.0128	0.0176	CbGbCtD
Atazanavir—CYP3A4—Doxorubicin—urinary bladder cancer	0.00875	0.012	CbGbCtD
Atazanavir—CYP2C9—urine—urinary bladder cancer	0.000869	0.182	CbGeAlD
Atazanavir—CYP3A4—urine—urinary bladder cancer	0.000663	0.138	CbGeAlD
Atazanavir—SLCO1B3—vagina—urinary bladder cancer	0.000527	0.11	CbGeAlD
Atazanavir—ABCC1—prostate gland—urinary bladder cancer	0.000413	0.0862	CbGeAlD
Atazanavir—ABCC1—seminal vesicle—urinary bladder cancer	0.000349	0.0729	CbGeAlD
Atazanavir—ABCC1—urethra—urinary bladder cancer	0.000276	0.0577	CbGeAlD
Atazanavir—ABCC1—vagina—urinary bladder cancer	0.000204	0.0425	CbGeAlD
Atazanavir—CYP2C9—female reproductive system—urinary bladder cancer	0.00017	0.0356	CbGeAlD
Atazanavir—ABCB1—prostate gland—urinary bladder cancer	0.000168	0.0352	CbGeAlD
Atazanavir—CYP3A4—renal system—urinary bladder cancer	0.000162	0.0339	CbGeAlD
Atazanavir—Hepatitis—Methotrexate—urinary bladder cancer	0.000157	0.000686	CcSEcCtD
Atazanavir—Sweating—Epirubicin—urinary bladder cancer	0.000156	0.000685	CcSEcCtD
Atazanavir—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000156	0.000685	CcSEcCtD
Atazanavir—Asthenia—Gemcitabine—urinary bladder cancer	0.000156	0.000683	CcSEcCtD
Atazanavir—Haematuria—Epirubicin—urinary bladder cancer	0.000156	0.000682	CcSEcCtD
Atazanavir—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000155	0.000677	CcSEcCtD
Atazanavir—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000155	0.000677	CcSEcCtD
Atazanavir—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000154	0.000676	CcSEcCtD
Atazanavir—Weight increased—Doxorubicin—urinary bladder cancer	0.000154	0.000675	CcSEcCtD
Atazanavir—Pruritus—Gemcitabine—urinary bladder cancer	0.000154	0.000674	CcSEcCtD
Atazanavir—Nausea—Thiotepa—urinary bladder cancer	0.000154	0.000673	CcSEcCtD
Atazanavir—Urethral disorder—Methotrexate—urinary bladder cancer	0.000153	0.000672	CcSEcCtD
Atazanavir—Weight decreased—Doxorubicin—urinary bladder cancer	0.000153	0.000671	CcSEcCtD
Atazanavir—Feeling abnormal—Etoposide—urinary bladder cancer	0.000153	0.00067	CcSEcCtD
Atazanavir—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000153	0.000669	CcSEcCtD
Atazanavir—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000152	0.000665	CcSEcCtD
Atazanavir—Pruritus—Fluorouracil—urinary bladder cancer	0.000151	0.000663	CcSEcCtD
Atazanavir—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.00015	0.000656	CcSEcCtD
Atazanavir—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000149	0.000654	CcSEcCtD
Atazanavir—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000149	0.000652	CcSEcCtD
Atazanavir—Renal failure—Doxorubicin—urinary bladder cancer	0.000148	0.00065	CcSEcCtD
Atazanavir—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000148	0.000648	CcSEcCtD
Atazanavir—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000148	0.000648	CcSEcCtD
Atazanavir—Urticaria—Etoposide—urinary bladder cancer	0.000148	0.000646	CcSEcCtD
Atazanavir—Stomatitis—Doxorubicin—urinary bladder cancer	0.000147	0.000645	CcSEcCtD
Atazanavir—Jaundice—Doxorubicin—urinary bladder cancer	0.000147	0.000645	CcSEcCtD
Atazanavir—Abdominal pain—Etoposide—urinary bladder cancer	0.000147	0.000643	CcSEcCtD
Atazanavir—Body temperature increased—Etoposide—urinary bladder cancer	0.000147	0.000643	CcSEcCtD
Atazanavir—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000147	0.000643	CcSEcCtD
Atazanavir—Hepatitis—Epirubicin—urinary bladder cancer	0.000147	0.000642	CcSEcCtD
Atazanavir—Eye disorder—Methotrexate—urinary bladder cancer	0.000146	0.000641	CcSEcCtD
Atazanavir—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000146	0.000641	CcSEcCtD
Atazanavir—Tinnitus—Methotrexate—urinary bladder cancer	0.000146	0.000639	CcSEcCtD
Atazanavir—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000146	0.000639	CcSEcCtD
Atazanavir—Asthenia—Cisplatin—urinary bladder cancer	0.000145	0.000637	CcSEcCtD
Atazanavir—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000145	0.000636	CcSEcCtD
Atazanavir—Sweating—Doxorubicin—urinary bladder cancer	0.000145	0.000634	CcSEcCtD
Atazanavir—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000145	0.000634	CcSEcCtD
Atazanavir—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000144	0.000632	CcSEcCtD
Atazanavir—Haematuria—Doxorubicin—urinary bladder cancer	0.000144	0.000631	CcSEcCtD
Atazanavir—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000144	0.000631	CcSEcCtD
Atazanavir—Urethral disorder—Epirubicin—urinary bladder cancer	0.000144	0.000629	CcSEcCtD
Atazanavir—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000143	0.000626	CcSEcCtD
Atazanavir—ABCB1—seminal vesicle—urinary bladder cancer	0.000142	0.0298	CbGeAlD
Atazanavir—Angiopathy—Methotrexate—urinary bladder cancer	0.000142	0.000622	CcSEcCtD
Atazanavir—Immune system disorder—Methotrexate—urinary bladder cancer	0.000141	0.000619	CcSEcCtD
Atazanavir—Dizziness—Fluorouracil—urinary bladder cancer	0.000141	0.000619	CcSEcCtD
Atazanavir—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000141	0.000618	CcSEcCtD
Atazanavir—Diarrhoea—Cisplatin—urinary bladder cancer	0.000139	0.000607	CcSEcCtD
Atazanavir—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000139	0.000607	CcSEcCtD
Atazanavir—Alopecia—Methotrexate—urinary bladder cancer	0.000138	0.000606	CcSEcCtD
Atazanavir—Vomiting—Gemcitabine—urinary bladder cancer	0.000138	0.000606	CcSEcCtD
Atazanavir—SLCO1B3—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000138	0.00375	CbGpPWpGaD
Atazanavir—Mental disorder—Methotrexate—urinary bladder cancer	0.000137	0.000601	CcSEcCtD
Atazanavir—Rash—Gemcitabine—urinary bladder cancer	0.000137	0.000601	CcSEcCtD
Atazanavir—Dermatitis—Gemcitabine—urinary bladder cancer	0.000137	0.0006	CcSEcCtD
Atazanavir—Eye disorder—Epirubicin—urinary bladder cancer	0.000137	0.0006	CcSEcCtD
Atazanavir—Hypersensitivity—Etoposide—urinary bladder cancer	0.000137	0.000599	CcSEcCtD
Atazanavir—Tinnitus—Epirubicin—urinary bladder cancer	0.000137	0.000598	CcSEcCtD
Atazanavir—Malnutrition—Methotrexate—urinary bladder cancer	0.000136	0.000597	CcSEcCtD
Atazanavir—Headache—Gemcitabine—urinary bladder cancer	0.000136	0.000597	CcSEcCtD
Atazanavir—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000136	0.000596	CcSEcCtD
Atazanavir—Vomiting—Fluorouracil—urinary bladder cancer	0.000136	0.000595	CcSEcCtD
Atazanavir—Hepatitis—Doxorubicin—urinary bladder cancer	0.000136	0.000594	CcSEcCtD
Atazanavir—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000135	0.000591	CcSEcCtD
Atazanavir—Rash—Fluorouracil—urinary bladder cancer	0.000135	0.00059	CcSEcCtD
Atazanavir—Dermatitis—Fluorouracil—urinary bladder cancer	0.000135	0.00059	CcSEcCtD
Atazanavir—Headache—Fluorouracil—urinary bladder cancer	0.000134	0.000587	CcSEcCtD
Atazanavir—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000134	0.000586	CcSEcCtD
Atazanavir—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000134	0.000585	CcSEcCtD
Atazanavir—Dysgeusia—Methotrexate—urinary bladder cancer	0.000133	0.000585	CcSEcCtD
Atazanavir—Asthenia—Etoposide—urinary bladder cancer	0.000133	0.000584	CcSEcCtD
Atazanavir—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000133	0.000583	CcSEcCtD
Atazanavir—Angiopathy—Epirubicin—urinary bladder cancer	0.000133	0.000582	CcSEcCtD
Atazanavir—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000133	0.000582	CcSEcCtD
Atazanavir—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000133	0.00361	CbGpPWpGaD
Atazanavir—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000133	0.00361	CbGpPWpGaD
Atazanavir—Immune system disorder—Epirubicin—urinary bladder cancer	0.000132	0.00058	CcSEcCtD
Atazanavir—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000132	0.000578	CcSEcCtD
Atazanavir—Back pain—Methotrexate—urinary bladder cancer	0.000132	0.000577	CcSEcCtD
Atazanavir—ABCC1—lymph node—urinary bladder cancer	0.000132	0.0275	CbGeAlD
Atazanavir—Pruritus—Etoposide—urinary bladder cancer	0.000131	0.000575	CcSEcCtD
Atazanavir—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000131	0.00356	CbGpPWpGaD
Atazanavir—CYP3A4—female reproductive system—urinary bladder cancer	0.00013	0.0271	CbGeAlD
Atazanavir—Alopecia—Epirubicin—urinary bladder cancer	0.000129	0.000567	CcSEcCtD
Atazanavir—Nausea—Gemcitabine—urinary bladder cancer	0.000129	0.000566	CcSEcCtD
Atazanavir—Vomiting—Cisplatin—urinary bladder cancer	0.000129	0.000564	CcSEcCtD
Atazanavir—Mental disorder—Epirubicin—urinary bladder cancer	0.000128	0.000562	CcSEcCtD
Atazanavir—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000128	0.000561	CcSEcCtD
Atazanavir—Rash—Cisplatin—urinary bladder cancer	0.000128	0.00056	CcSEcCtD
Atazanavir—Dermatitis—Cisplatin—urinary bladder cancer	0.000128	0.000559	CcSEcCtD
Atazanavir—Malnutrition—Epirubicin—urinary bladder cancer	0.000128	0.000559	CcSEcCtD
Atazanavir—Diarrhoea—Etoposide—urinary bladder cancer	0.000127	0.000556	CcSEcCtD
Atazanavir—Nausea—Fluorouracil—urinary bladder cancer	0.000127	0.000556	CcSEcCtD
Atazanavir—Eye disorder—Doxorubicin—urinary bladder cancer	0.000127	0.000555	CcSEcCtD
Atazanavir—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000126	0.000554	CcSEcCtD
Atazanavir—Tinnitus—Doxorubicin—urinary bladder cancer	0.000126	0.000554	CcSEcCtD
Atazanavir—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000126	0.000551	CcSEcCtD
Atazanavir—Flatulence—Epirubicin—urinary bladder cancer	0.000126	0.00055	CcSEcCtD
Atazanavir—Tension—Epirubicin—urinary bladder cancer	0.000125	0.000548	CcSEcCtD
Atazanavir—Dysgeusia—Epirubicin—urinary bladder cancer	0.000125	0.000547	CcSEcCtD
Atazanavir—Nervousness—Epirubicin—urinary bladder cancer	0.000124	0.000543	CcSEcCtD
Atazanavir—ABCB1—epithelium—urinary bladder cancer	0.000124	0.0259	CbGeAlD
Atazanavir—Back pain—Epirubicin—urinary bladder cancer	0.000123	0.00054	CcSEcCtD
Atazanavir—Angiopathy—Doxorubicin—urinary bladder cancer	0.000123	0.000539	CcSEcCtD
Atazanavir—Malaise—Methotrexate—urinary bladder cancer	0.000123	0.000538	CcSEcCtD
Atazanavir—Dizziness—Etoposide—urinary bladder cancer	0.000123	0.000538	CcSEcCtD
Atazanavir—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000122	0.000536	CcSEcCtD
Atazanavir—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000122	0.000535	CcSEcCtD
Atazanavir—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000121	0.0033	CbGpPWpGaD
Atazanavir—Nausea—Cisplatin—urinary bladder cancer	0.00012	0.000527	CcSEcCtD
Atazanavir—Alopecia—Doxorubicin—urinary bladder cancer	0.00012	0.000525	CcSEcCtD
Atazanavir—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00012	0.00325	CbGpPWpGaD
Atazanavir—ABCC1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000119	0.00325	CbGpPWpGaD
Atazanavir—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—urinary bladder cancer	0.000119	0.00324	CbGpPWpGaD
Atazanavir—Cough—Methotrexate—urinary bladder cancer	0.000119	0.000521	CcSEcCtD
Atazanavir—Mental disorder—Doxorubicin—urinary bladder cancer	0.000119	0.00052	CcSEcCtD
Atazanavir—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000118	0.000518	CcSEcCtD
Atazanavir—Convulsion—Methotrexate—urinary bladder cancer	0.000118	0.000517	CcSEcCtD
Atazanavir—Vomiting—Etoposide—urinary bladder cancer	0.000118	0.000517	CcSEcCtD
Atazanavir—Malnutrition—Doxorubicin—urinary bladder cancer	0.000118	0.000517	CcSEcCtD
Atazanavir—Agitation—Epirubicin—urinary bladder cancer	0.000117	0.000513	CcSEcCtD
Atazanavir—Rash—Etoposide—urinary bladder cancer	0.000117	0.000513	CcSEcCtD
Atazanavir—Dermatitis—Etoposide—urinary bladder cancer	0.000117	0.000512	CcSEcCtD
Atazanavir—Headache—Etoposide—urinary bladder cancer	0.000116	0.00051	CcSEcCtD
Atazanavir—Flatulence—Doxorubicin—urinary bladder cancer	0.000116	0.000509	CcSEcCtD
Atazanavir—Chest pain—Methotrexate—urinary bladder cancer	0.000116	0.000508	CcSEcCtD
Atazanavir—Arthralgia—Methotrexate—urinary bladder cancer	0.000116	0.000508	CcSEcCtD
Atazanavir—Myalgia—Methotrexate—urinary bladder cancer	0.000116	0.000508	CcSEcCtD
Atazanavir—Tension—Doxorubicin—urinary bladder cancer	0.000116	0.000507	CcSEcCtD
Atazanavir—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000116	0.000506	CcSEcCtD
Atazanavir—SLCO1B3—Metabolism—GSTZ1—urinary bladder cancer	0.000115	0.00314	CbGpPWpGaD
Atazanavir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000115	0.000505	CcSEcCtD
Atazanavir—Malaise—Epirubicin—urinary bladder cancer	0.000115	0.000504	CcSEcCtD
Atazanavir—ABCB1—renal system—urinary bladder cancer	0.000115	0.024	CbGeAlD
Atazanavir—Discomfort—Methotrexate—urinary bladder cancer	0.000115	0.000502	CcSEcCtD
Atazanavir—Nervousness—Doxorubicin—urinary bladder cancer	0.000115	0.000502	CcSEcCtD
Atazanavir—Syncope—Epirubicin—urinary bladder cancer	0.000114	0.000501	CcSEcCtD
Atazanavir—Back pain—Doxorubicin—urinary bladder cancer	0.000114	0.0005	CcSEcCtD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.000114	0.00309	CbGpPWpGaD
Atazanavir—ABCB1—urethra—urinary bladder cancer	0.000113	0.0236	CbGeAlD
Atazanavir—Palpitations—Epirubicin—urinary bladder cancer	0.000113	0.000494	CcSEcCtD
Atazanavir—Confusional state—Methotrexate—urinary bladder cancer	0.000112	0.000491	CcSEcCtD
Atazanavir—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000112	0.000491	CcSEcCtD
Atazanavir—Cough—Epirubicin—urinary bladder cancer	0.000111	0.000487	CcSEcCtD
Atazanavir—Convulsion—Epirubicin—urinary bladder cancer	0.000111	0.000484	CcSEcCtD
Atazanavir—Infection—Methotrexate—urinary bladder cancer	0.000111	0.000484	CcSEcCtD
Atazanavir—ABCB1—HIF-1-alpha transcription factor network—TERT—urinary bladder cancer	0.00011	0.00301	CbGpPWpGaD
Atazanavir—Nausea—Etoposide—urinary bladder cancer	0.00011	0.000483	CcSEcCtD
Atazanavir—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	0.00011	0.003	CbGpPWpGaD
Atazanavir—Hypertension—Epirubicin—urinary bladder cancer	0.00011	0.000482	CcSEcCtD
Atazanavir—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000109	0.00048	CcSEcCtD
Atazanavir—SLCO1B3—Metabolism—GSTO2—urinary bladder cancer	0.000109	0.00298	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—NAT1—urinary bladder cancer	0.000109	0.00298	CbGpPWpGaD
Atazanavir—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000109	0.00297	CbGpPWpGaD
Atazanavir—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000109	0.000478	CcSEcCtD
Atazanavir—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000109	0.00296	CbGpPWpGaD
Atazanavir—Arthralgia—Epirubicin—urinary bladder cancer	0.000109	0.000476	CcSEcCtD
Atazanavir—Chest pain—Epirubicin—urinary bladder cancer	0.000109	0.000476	CcSEcCtD
Atazanavir—Myalgia—Epirubicin—urinary bladder cancer	0.000109	0.000476	CcSEcCtD
Atazanavir—Agitation—Doxorubicin—urinary bladder cancer	0.000108	0.000475	CcSEcCtD
Atazanavir—Anxiety—Epirubicin—urinary bladder cancer	0.000108	0.000474	CcSEcCtD
Atazanavir—Skin disorder—Methotrexate—urinary bladder cancer	0.000108	0.000473	CcSEcCtD
Atazanavir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000108	0.000472	CcSEcCtD
Atazanavir—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000108	0.00293	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000108	0.00293	CbGpPWpGaD
Atazanavir—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000108	0.000471	CcSEcCtD
Atazanavir—Discomfort—Epirubicin—urinary bladder cancer	0.000107	0.00047	CcSEcCtD
Atazanavir—Malaise—Doxorubicin—urinary bladder cancer	0.000106	0.000466	CcSEcCtD
Atazanavir—Dry mouth—Epirubicin—urinary bladder cancer	0.000106	0.000465	CcSEcCtD
Atazanavir—Anorexia—Methotrexate—urinary bladder cancer	0.000106	0.000464	CcSEcCtD
Atazanavir—Syncope—Doxorubicin—urinary bladder cancer	0.000106	0.000464	CcSEcCtD
Atazanavir—Confusional state—Epirubicin—urinary bladder cancer	0.000105	0.00046	CcSEcCtD
Atazanavir—Palpitations—Doxorubicin—urinary bladder cancer	0.000104	0.000457	CcSEcCtD
Atazanavir—Oedema—Epirubicin—urinary bladder cancer	0.000104	0.000456	CcSEcCtD
Atazanavir—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000104	0.000454	CcSEcCtD
Atazanavir—Infection—Epirubicin—urinary bladder cancer	0.000103	0.000453	CcSEcCtD
Atazanavir—Cough—Doxorubicin—urinary bladder cancer	0.000103	0.000451	CcSEcCtD
Atazanavir—Shock—Epirubicin—urinary bladder cancer	0.000102	0.000449	CcSEcCtD
Atazanavir—Convulsion—Doxorubicin—urinary bladder cancer	0.000102	0.000448	CcSEcCtD
Atazanavir—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000102	0.000447	CcSEcCtD
Atazanavir—Hypertension—Doxorubicin—urinary bladder cancer	0.000102	0.000446	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000101	0.000444	CcSEcCtD
Atazanavir—Skin disorder—Epirubicin—urinary bladder cancer	0.000101	0.000443	CcSEcCtD
Atazanavir—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000101	0.000441	CcSEcCtD
Atazanavir—Insomnia—Methotrexate—urinary bladder cancer	0.000101	0.000441	CcSEcCtD
Atazanavir—Arthralgia—Doxorubicin—urinary bladder cancer	0.0001	0.00044	CcSEcCtD
Atazanavir—Myalgia—Doxorubicin—urinary bladder cancer	0.0001	0.00044	CcSEcCtD
Atazanavir—Chest pain—Doxorubicin—urinary bladder cancer	0.0001	0.00044	CcSEcCtD
Atazanavir—SLCO1B3—Metabolism—UGT2B7—urinary bladder cancer	0.0001	0.00272	CbGpPWpGaD
Atazanavir—Anxiety—Doxorubicin—urinary bladder cancer	0.0001	0.000439	CcSEcCtD
Atazanavir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	9.98e-05	0.000437	CcSEcCtD
Atazanavir—Discomfort—Doxorubicin—urinary bladder cancer	9.93e-05	0.000435	CcSEcCtD
Atazanavir—Anorexia—Epirubicin—urinary bladder cancer	9.92e-05	0.000435	CcSEcCtD
Atazanavir—Dyspnoea—Methotrexate—urinary bladder cancer	9.92e-05	0.000434	CcSEcCtD
Atazanavir—Somnolence—Methotrexate—urinary bladder cancer	9.89e-05	0.000433	CcSEcCtD
Atazanavir—Dry mouth—Doxorubicin—urinary bladder cancer	9.83e-05	0.00043	CcSEcCtD
Atazanavir—Dyspepsia—Methotrexate—urinary bladder cancer	9.79e-05	0.000429	CcSEcCtD
Atazanavir—ABCC1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	9.74e-05	0.00265	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—FAS—urinary bladder cancer	9.73e-05	0.00265	CbGpPWpGaD
Atazanavir—Confusional state—Doxorubicin—urinary bladder cancer	9.71e-05	0.000425	CcSEcCtD
Atazanavir—Decreased appetite—Methotrexate—urinary bladder cancer	9.67e-05	0.000424	CcSEcCtD
Atazanavir—Oedema—Doxorubicin—urinary bladder cancer	9.63e-05	0.000422	CcSEcCtD
Atazanavir—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	9.6e-05	0.000421	CcSEcCtD
Atazanavir—Fatigue—Methotrexate—urinary bladder cancer	9.59e-05	0.00042	CcSEcCtD
Atazanavir—Infection—Doxorubicin—urinary bladder cancer	9.57e-05	0.000419	CcSEcCtD
Atazanavir—Pain—Methotrexate—urinary bladder cancer	9.51e-05	0.000417	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	9.48e-05	0.000415	CcSEcCtD
Atazanavir—Shock—Doxorubicin—urinary bladder cancer	9.48e-05	0.000415	CcSEcCtD
Atazanavir—Nervous system disorder—Doxorubicin—urinary bladder cancer	9.45e-05	0.000414	CcSEcCtD
Atazanavir—Insomnia—Epirubicin—urinary bladder cancer	9.41e-05	0.000412	CcSEcCtD
Atazanavir—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	9.41e-05	0.00256	CbGpPWpGaD
Atazanavir—Skin disorder—Doxorubicin—urinary bladder cancer	9.36e-05	0.00041	CcSEcCtD
Atazanavir—Hyperhidrosis—Doxorubicin—urinary bladder cancer	9.31e-05	0.000408	CcSEcCtD
Atazanavir—SLCO1B3—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	9.31e-05	0.00253	CbGpPWpGaD
Atazanavir—Dyspnoea—Epirubicin—urinary bladder cancer	9.28e-05	0.000406	CcSEcCtD
Atazanavir—Somnolence—Epirubicin—urinary bladder cancer	9.25e-05	0.000405	CcSEcCtD
Atazanavir—ABCC1—Disease—GSTO2—urinary bladder cancer	9.24e-05	0.00251	CbGpPWpGaD
Atazanavir—ABCB1—female reproductive system—urinary bladder cancer	9.19e-05	0.0192	CbGeAlD
Atazanavir—Anorexia—Doxorubicin—urinary bladder cancer	9.18e-05	0.000402	CcSEcCtD
Atazanavir—Feeling abnormal—Methotrexate—urinary bladder cancer	9.17e-05	0.000401	CcSEcCtD
Atazanavir—Dyspepsia—Epirubicin—urinary bladder cancer	9.16e-05	0.000401	CcSEcCtD
Atazanavir—Gastrointestinal pain—Methotrexate—urinary bladder cancer	9.1e-05	0.000398	CcSEcCtD
Atazanavir—Decreased appetite—Epirubicin—urinary bladder cancer	9.05e-05	0.000396	CcSEcCtD
Atazanavir—SLCO1B3—Metabolism—CYP4B1—urinary bladder cancer	9.01e-05	0.00245	CbGpPWpGaD
Atazanavir—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	8.99e-05	0.000394	CcSEcCtD
Atazanavir—Fatigue—Epirubicin—urinary bladder cancer	8.97e-05	0.000393	CcSEcCtD
Atazanavir—Pain—Epirubicin—urinary bladder cancer	8.9e-05	0.00039	CcSEcCtD
Atazanavir—Constipation—Epirubicin—urinary bladder cancer	8.9e-05	0.00039	CcSEcCtD
Atazanavir—Urticaria—Methotrexate—urinary bladder cancer	8.84e-05	0.000387	CcSEcCtD
Atazanavir—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	8.81e-05	0.0024	CbGpPWpGaD
Atazanavir—Abdominal pain—Methotrexate—urinary bladder cancer	8.79e-05	0.000385	CcSEcCtD
Atazanavir—Body temperature increased—Methotrexate—urinary bladder cancer	8.79e-05	0.000385	CcSEcCtD
Atazanavir—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	8.77e-05	0.000384	CcSEcCtD
Atazanavir—Insomnia—Doxorubicin—urinary bladder cancer	8.71e-05	0.000382	CcSEcCtD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	8.67e-05	0.00236	CbGpPWpGaD
Atazanavir—ABCB1—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	8.63e-05	0.00235	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	8.62e-05	0.00234	CbGpPWpGaD
Atazanavir—Dyspnoea—Doxorubicin—urinary bladder cancer	8.59e-05	0.000376	CcSEcCtD
Atazanavir—Feeling abnormal—Epirubicin—urinary bladder cancer	8.58e-05	0.000376	CcSEcCtD
Atazanavir—Somnolence—Doxorubicin—urinary bladder cancer	8.56e-05	0.000375	CcSEcCtD
Atazanavir—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	8.55e-05	0.00232	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—SLC19A1—urinary bladder cancer	8.51e-05	0.00232	CbGpPWpGaD
Atazanavir—Gastrointestinal pain—Epirubicin—urinary bladder cancer	8.51e-05	0.000373	CcSEcCtD
Atazanavir—Dyspepsia—Doxorubicin—urinary bladder cancer	8.48e-05	0.000371	CcSEcCtD
Atazanavir—Decreased appetite—Doxorubicin—urinary bladder cancer	8.37e-05	0.000367	CcSEcCtD
Atazanavir—ABCB1—vagina—urinary bladder cancer	8.32e-05	0.0174	CbGeAlD
Atazanavir—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	8.31e-05	0.000364	CcSEcCtD
Atazanavir—Fatigue—Doxorubicin—urinary bladder cancer	8.3e-05	0.000364	CcSEcCtD
Atazanavir—SLCO1B3—Metabolism—PRSS3—urinary bladder cancer	8.3e-05	0.00226	CbGpPWpGaD
Atazanavir—Urticaria—Epirubicin—urinary bladder cancer	8.27e-05	0.000362	CcSEcCtD
Atazanavir—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	8.24e-05	0.00224	CbGpPWpGaD
Atazanavir—Pain—Doxorubicin—urinary bladder cancer	8.24e-05	0.000361	CcSEcCtD
Atazanavir—Constipation—Doxorubicin—urinary bladder cancer	8.24e-05	0.000361	CcSEcCtD
Atazanavir—Body temperature increased—Epirubicin—urinary bladder cancer	8.23e-05	0.00036	CcSEcCtD
Atazanavir—Abdominal pain—Epirubicin—urinary bladder cancer	8.23e-05	0.00036	CcSEcCtD
Atazanavir—Hypersensitivity—Methotrexate—urinary bladder cancer	8.19e-05	0.000359	CcSEcCtD
Atazanavir—ABCC1—Metabolism—GSTZ1—urinary bladder cancer	8.16e-05	0.00222	CbGpPWpGaD
Atazanavir—Asthenia—Methotrexate—urinary bladder cancer	7.98e-05	0.00035	CcSEcCtD
Atazanavir—Feeling abnormal—Doxorubicin—urinary bladder cancer	7.94e-05	0.000348	CcSEcCtD
Atazanavir—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	7.88e-05	0.000345	CcSEcCtD
Atazanavir—Pruritus—Methotrexate—urinary bladder cancer	7.87e-05	0.000345	CcSEcCtD
Atazanavir—ABCB1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	7.86e-05	0.00214	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—GSTO2—urinary bladder cancer	7.74e-05	0.00211	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—NAT1—urinary bladder cancer	7.74e-05	0.00211	CbGpPWpGaD
Atazanavir—Hypersensitivity—Epirubicin—urinary bladder cancer	7.67e-05	0.000336	CcSEcCtD
Atazanavir—Urticaria—Doxorubicin—urinary bladder cancer	7.65e-05	0.000335	CcSEcCtD
Atazanavir—Body temperature increased—Doxorubicin—urinary bladder cancer	7.61e-05	0.000333	CcSEcCtD
Atazanavir—Abdominal pain—Doxorubicin—urinary bladder cancer	7.61e-05	0.000333	CcSEcCtD
Atazanavir—ABCC1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	7.61e-05	0.00207	CbGpPWpGaD
Atazanavir—Diarrhoea—Methotrexate—urinary bladder cancer	7.61e-05	0.000333	CcSEcCtD
Atazanavir—Asthenia—Epirubicin—urinary bladder cancer	7.47e-05	0.000327	CcSEcCtD
Atazanavir—Pruritus—Epirubicin—urinary bladder cancer	7.36e-05	0.000323	CcSEcCtD
Atazanavir—Dizziness—Methotrexate—urinary bladder cancer	7.36e-05	0.000322	CcSEcCtD
Atazanavir—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	7.27e-05	0.00198	CbGpPWpGaD
Atazanavir—ABCC1—Disease—SLC19A1—urinary bladder cancer	7.19e-05	0.00195	CbGpPWpGaD
Atazanavir—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	7.17e-05	0.00195	CbGpPWpGaD
Atazanavir—Diarrhoea—Epirubicin—urinary bladder cancer	7.12e-05	0.000312	CcSEcCtD
Atazanavir—Hypersensitivity—Doxorubicin—urinary bladder cancer	7.1e-05	0.000311	CcSEcCtD
Atazanavir—ABCC1—Metabolism—UGT2B7—urinary bladder cancer	7.08e-05	0.00193	CbGpPWpGaD
Atazanavir—Vomiting—Methotrexate—urinary bladder cancer	7.07e-05	0.00031	CcSEcCtD
Atazanavir—Rash—Methotrexate—urinary bladder cancer	7.01e-05	0.000307	CcSEcCtD
Atazanavir—Dermatitis—Methotrexate—urinary bladder cancer	7.01e-05	0.000307	CcSEcCtD
Atazanavir—ABCC1—Disease—PRSS3—urinary bladder cancer	7e-05	0.00191	CbGpPWpGaD
Atazanavir—Headache—Methotrexate—urinary bladder cancer	6.97e-05	0.000305	CcSEcCtD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	6.94e-05	0.00189	CbGpPWpGaD
Atazanavir—Asthenia—Doxorubicin—urinary bladder cancer	6.91e-05	0.000303	CcSEcCtD
Atazanavir—Dizziness—Epirubicin—urinary bladder cancer	6.88e-05	0.000301	CcSEcCtD
Atazanavir—Pruritus—Doxorubicin—urinary bladder cancer	6.81e-05	0.000298	CcSEcCtD
Atazanavir—ABCC1—Disease—HDAC4—urinary bladder cancer	6.68e-05	0.00182	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	6.65e-05	0.00181	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—TYMP—urinary bladder cancer	6.63e-05	0.0018	CbGpPWpGaD
Atazanavir—Vomiting—Epirubicin—urinary bladder cancer	6.62e-05	0.00029	CcSEcCtD
Atazanavir—Nausea—Methotrexate—urinary bladder cancer	6.61e-05	0.000289	CcSEcCtD
Atazanavir—Diarrhoea—Doxorubicin—urinary bladder cancer	6.59e-05	0.000289	CcSEcCtD
Atazanavir—ABCC1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	6.58e-05	0.00179	CbGpPWpGaD
Atazanavir—Rash—Epirubicin—urinary bladder cancer	6.56e-05	0.000287	CcSEcCtD
Atazanavir—Dermatitis—Epirubicin—urinary bladder cancer	6.56e-05	0.000287	CcSEcCtD
Atazanavir—Headache—Epirubicin—urinary bladder cancer	6.52e-05	0.000286	CcSEcCtD
Atazanavir—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	6.5e-05	0.00177	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—CYP4B1—urinary bladder cancer	6.37e-05	0.00173	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	6.37e-05	0.00173	CbGpPWpGaD
Atazanavir—Dizziness—Doxorubicin—urinary bladder cancer	6.37e-05	0.000279	CcSEcCtD
Atazanavir—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	6.36e-05	0.00173	CbGpPWpGaD
Atazanavir—Nausea—Epirubicin—urinary bladder cancer	6.18e-05	0.000271	CcSEcCtD
Atazanavir—Vomiting—Doxorubicin—urinary bladder cancer	6.12e-05	0.000268	CcSEcCtD
Atazanavir—Rash—Doxorubicin—urinary bladder cancer	6.07e-05	0.000266	CcSEcCtD
Atazanavir—Dermatitis—Doxorubicin—urinary bladder cancer	6.07e-05	0.000266	CcSEcCtD
Atazanavir—Headache—Doxorubicin—urinary bladder cancer	6.03e-05	0.000264	CcSEcCtD
Atazanavir—ABCC1—Metabolism—SLC19A1—urinary bladder cancer	6.02e-05	0.00164	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—NAT2—urinary bladder cancer	6e-05	0.00163	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	5.94e-05	0.00161	CbGpPWpGaD
Atazanavir—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	5.92e-05	0.00161	CbGpPWpGaD
Atazanavir—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	5.88e-05	0.0016	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—PRSS3—urinary bladder cancer	5.87e-05	0.0016	CbGpPWpGaD
Atazanavir—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	5.84e-05	0.00159	CbGpPWpGaD
Atazanavir—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	5.81e-05	0.00158	CbGpPWpGaD
Atazanavir—Nausea—Doxorubicin—urinary bladder cancer	5.72e-05	0.000251	CcSEcCtD
Atazanavir—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	5.68e-05	0.00155	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	5.67e-05	0.00154	CbGpPWpGaD
Atazanavir—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	5.64e-05	0.00153	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	5.52e-05	0.0015	CbGpPWpGaD
Atazanavir—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	5.44e-05	0.00148	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	5.42e-05	0.00147	CbGpPWpGaD
Atazanavir—ABCB1—lymph node—urinary bladder cancer	5.38e-05	0.0112	CbGeAlD
Atazanavir—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	5.37e-05	0.00146	CbGpPWpGaD
Atazanavir—ABCC1—Disease—LIG1—urinary bladder cancer	5.31e-05	0.00144	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—RRM2—urinary bladder cancer	5.18e-05	0.00141	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	4.8e-05	0.00131	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—ENO2—urinary bladder cancer	4.8e-05	0.0013	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—HPGDS—urinary bladder cancer	4.8e-05	0.0013	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.77e-05	0.0013	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.7e-05	0.00128	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—TYMP—urinary bladder cancer	4.69e-05	0.00128	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—GSTT1—urinary bladder cancer	4.65e-05	0.00127	CbGpPWpGaD
Atazanavir—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	4.63e-05	0.00126	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.58e-05	0.00125	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.5e-05	0.00123	CbGpPWpGaD
Atazanavir—SLCO1B3—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.35e-05	0.00118	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	4.24e-05	0.00115	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—NAT2—urinary bladder cancer	4.24e-05	0.00115	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	4.23e-05	0.00115	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	4.21e-05	0.00114	CbGpPWpGaD
Atazanavir—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	4.13e-05	0.00112	CbGpPWpGaD
Atazanavir—ABCC1—Disease—ENO2—urinary bladder cancer	4.05e-05	0.0011	CbGpPWpGaD
Atazanavir—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	3.91e-05	0.00106	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	3.88e-05	0.00106	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—NQO1—urinary bladder cancer	3.87e-05	0.00105	CbGpPWpGaD
Atazanavir—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.85e-05	0.00105	CbGpPWpGaD
Atazanavir—ABCC1—Disease—RBX1—urinary bladder cancer	3.84e-05	0.00104	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.75e-05	0.00102	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	3.69e-05	0.001	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—NAT1—urinary bladder cancer	3.68e-05	0.001	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—GSTO2—urinary bladder cancer	3.68e-05	0.001	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—RRM2—urinary bladder cancer	3.66e-05	0.000996	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	3.64e-05	0.000991	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	3.63e-05	0.000987	CbGpPWpGaD
Atazanavir—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	3.59e-05	0.000976	CbGpPWpGaD
Atazanavir—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.54e-05	0.000963	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	3.44e-05	0.000936	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—NAT1—urinary bladder cancer	3.44e-05	0.000936	CbGpPWpGaD
Atazanavir—ABCC1—Disease—JAG1—urinary bladder cancer	3.43e-05	0.000934	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—ENO2—urinary bladder cancer	3.39e-05	0.000922	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—HPGDS—urinary bladder cancer	3.39e-05	0.000922	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.38e-05	0.00092	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.37e-05	0.000917	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	3.37e-05	0.000916	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—GSTT1—urinary bladder cancer	3.29e-05	0.000894	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.27e-05	0.00089	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.24e-05	0.000881	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—GSTP1—urinary bladder cancer	3.22e-05	0.000877	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	3.15e-05	0.000856	CbGpPWpGaD
Atazanavir—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	3.13e-05	0.000851	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.12e-05	0.000848	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	3.09e-05	0.00084	CbGpPWpGaD
Atazanavir—ABCC1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.08e-05	0.000837	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	3.03e-05	0.000825	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	3.02e-05	0.000822	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—TYMS—urinary bladder cancer	3e-05	0.000815	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—NCOR1—urinary bladder cancer	2.96e-05	0.000806	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—GSTM1—urinary bladder cancer	2.96e-05	0.000806	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	2.86e-05	0.000779	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—GPX1—urinary bladder cancer	2.84e-05	0.000772	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	2.83e-05	0.00077	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—PRSS3—urinary bladder cancer	2.79e-05	0.000759	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—ERCC2—urinary bladder cancer	2.79e-05	0.000758	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—NQO1—urinary bladder cancer	2.73e-05	0.000743	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	2.73e-05	0.000742	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	2.68e-05	0.000728	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.65e-05	0.000721	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	2.64e-05	0.000718	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	2.63e-05	0.000717	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—MTHFR—urinary bladder cancer	2.62e-05	0.000712	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	2.61e-05	0.000709	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	2.51e-05	0.000683	CbGpPWpGaD
Atazanavir—ABCC1—Disease—NCOR1—urinary bladder cancer	2.5e-05	0.00068	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	2.44e-05	0.000665	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	2.39e-05	0.000651	CbGpPWpGaD
Atazanavir—ABCC1—Disease—ERCC2—urinary bladder cancer	2.35e-05	0.00064	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.31e-05	0.000629	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—GSTP1—urinary bladder cancer	2.28e-05	0.00062	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	2.27e-05	0.000617	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—NAT1—urinary bladder cancer	2.27e-05	0.000617	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—TYMP—urinary bladder cancer	2.23e-05	0.000607	CbGpPWpGaD
Atazanavir—ABCC1—Disease—MTHFR—urinary bladder cancer	2.21e-05	0.000601	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.21e-05	0.0006	CbGpPWpGaD
Atazanavir—ABCC1—Disease—TERT—urinary bladder cancer	2.2e-05	0.0006	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.19e-05	0.000595	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.14e-05	0.000582	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—PPARG—urinary bladder cancer	2.12e-05	0.000577	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—TYMS—urinary bladder cancer	2.12e-05	0.000576	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—GSTM1—urinary bladder cancer	2.09e-05	0.00057	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—NCOR1—urinary bladder cancer	2.09e-05	0.00057	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.09e-05	0.000569	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—TYMP—urinary bladder cancer	2.08e-05	0.000567	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.07e-05	0.000564	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—CREBBP—urinary bladder cancer	2.04e-05	0.000555	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.04e-05	0.000555	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.02e-05	0.00055	CbGpPWpGaD
Atazanavir—ABCC1—Disease—FGFR3—urinary bladder cancer	2.02e-05	0.00055	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—NAT2—urinary bladder cancer	2.02e-05	0.000549	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—GPX1—urinary bladder cancer	2.01e-05	0.000546	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2e-05	0.000544	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—ERCC2—urinary bladder cancer	1.97e-05	0.000536	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—NAT2—urinary bladder cancer	1.88e-05	0.000513	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.87e-05	0.000508	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—MTHFR—urinary bladder cancer	1.85e-05	0.000503	CbGpPWpGaD
Atazanavir—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.8e-05	0.000489	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.76e-05	0.00048	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—RRM2—urinary bladder cancer	1.74e-05	0.000474	CbGpPWpGaD
Atazanavir—ABCC1—Disease—CREBBP—urinary bladder cancer	1.72e-05	0.000468	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.72e-05	0.000468	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—PTGS2—urinary bladder cancer	1.67e-05	0.000454	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—RRM2—urinary bladder cancer	1.63e-05	0.000443	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.61e-05	0.000439	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.61e-05	0.000439	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.56e-05	0.000426	CbGpPWpGaD
Atazanavir—ABCC1—Disease—RHOA—urinary bladder cancer	1.56e-05	0.000424	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	1.51e-05	0.00041	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—ENO2—urinary bladder cancer	1.51e-05	0.00041	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—PPARG—urinary bladder cancer	1.5e-05	0.000408	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.5e-05	0.000407	CbGpPWpGaD
Atazanavir—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.46e-05	0.000398	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	1.46e-05	0.000398	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—PTEN—urinary bladder cancer	1.46e-05	0.000396	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—CREBBP—urinary bladder cancer	1.44e-05	0.000392	CbGpPWpGaD
Atazanavir—ABCC1—Disease—ERBB2—urinary bladder cancer	1.44e-05	0.000392	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.44e-05	0.000391	CbGpPWpGaD
Atazanavir—ABCC1—Disease—PTGS2—urinary bladder cancer	1.41e-05	0.000384	CbGpPWpGaD
Atazanavir—SLCO1B3—Metabolism—EP300—urinary bladder cancer	1.39e-05	0.000378	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.37e-05	0.000374	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.3e-05	0.000354	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.24e-05	0.000338	CbGpPWpGaD
Atazanavir—ABCC1—Disease—CDKN1A—urinary bladder cancer	1.23e-05	0.000335	CbGpPWpGaD
Atazanavir—ABCC1—Disease—PTEN—urinary bladder cancer	1.23e-05	0.000334	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.21e-05	0.00033	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—PTGS2—urinary bladder cancer	1.18e-05	0.000321	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.18e-05	0.000321	CbGpPWpGaD
Atazanavir—ABCC1—Disease—EP300—urinary bladder cancer	1.17e-05	0.000319	CbGpPWpGaD
Atazanavir—ABCC1—Disease—SRC—urinary bladder cancer	1.14e-05	0.00031	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.08e-05	0.000295	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.07e-05	0.000292	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—PTEN—urinary bladder cancer	1.03e-05	0.00028	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.03e-05	0.00028	CbGpPWpGaD
Atazanavir—ABCC1—Disease—MYC—urinary bladder cancer	1.02e-05	0.000278	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.01e-05	0.000276	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.01e-05	0.000274	CbGpPWpGaD
Atazanavir—ABCC1—Disease—EGFR—urinary bladder cancer	9.99e-06	0.000272	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—GSTM1—urinary bladder cancer	9.96e-06	0.000271	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—NCOR1—urinary bladder cancer	9.96e-06	0.000271	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—ENO2—urinary bladder cancer	9.94e-06	0.00027	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	9.94e-06	0.00027	CbGpPWpGaD
Atazanavir—ABCC1—Metabolism—EP300—urinary bladder cancer	9.82e-06	0.000267	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.8e-06	0.000267	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	9.64e-06	0.000262	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—GPX1—urinary bladder cancer	9.54e-06	0.00026	CbGpPWpGaD
Atazanavir—ABCC1—Disease—KRAS—urinary bladder cancer	9.44e-06	0.000257	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—TYMS—urinary bladder cancer	9.42e-06	0.000256	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—ERCC2—urinary bladder cancer	9.37e-06	0.000255	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	9.31e-06	0.000253	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	9.31e-06	0.000253	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—GPX1—urinary bladder cancer	8.91e-06	0.000242	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—MTHFR—urinary bladder cancer	8.81e-06	0.00024	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	8.75e-06	0.000238	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	8.23e-06	0.000224	CbGpPWpGaD
Atazanavir—ABCC1—Disease—HRAS—urinary bladder cancer	8.03e-06	0.000218	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—NQO1—urinary bladder cancer	8.01e-06	0.000218	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—PPARG—urinary bladder cancer	7.14e-06	0.000194	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—CREBBP—urinary bladder cancer	6.86e-06	0.000187	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	6.68e-06	0.000182	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—PPARG—urinary bladder cancer	6.67e-06	0.000181	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	6.41e-06	0.000174	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—TYMS—urinary bladder cancer	6.21e-06	0.000169	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	6.14e-06	0.000167	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	6.14e-06	0.000167	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—GPX1—urinary bladder cancer	5.88e-06	0.00016	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	5.77e-06	0.000157	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—PTGS2—urinary bladder cancer	5.62e-06	0.000153	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	5.43e-06	0.000148	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	5.25e-06	0.000143	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—PTEN—urinary bladder cancer	4.9e-06	0.000133	CbGpPWpGaD
Atazanavir—ABCB1—Metabolism—EP300—urinary bladder cancer	4.67e-06	0.000127	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—PTEN—urinary bladder cancer	4.58e-06	0.000124	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—PPARG—urinary bladder cancer	4.4e-06	0.00012	CbGpPWpGaD
Atazanavir—CYP2C9—Metabolism—EP300—urinary bladder cancer	4.36e-06	0.000119	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	4.23e-06	0.000115	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.46e-06	9.41e-05	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.02e-06	8.21e-05	CbGpPWpGaD
Atazanavir—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.88e-06	7.83e-05	CbGpPWpGaD
